Söndag 18 Januari | 16:13:37 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-12 07:00 Kvartalsrapport 2026-Q3
2026-08-19 07:00 Kvartalsrapport 2026-Q2
2026-05-14 07:00 Kvartalsrapport 2026-Q1
2026-04-23 N/A Årsstämma
2026-02-19 07:00 Bokslutskommuniké 2025
2026-01-02 - Extra Bolagsstämma 2026
2025-11-12 - Extra Bolagsstämma 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-28 - X-dag ordinarie utdelning LIFE 0.00 NOK
2025-04-25 - Årsstämma
2025-02-20 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av microsensorer för diabetes. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-14 14:05:00

Reference is made to the stock exchange announcement published by Lifecare ASA (the “Company”) on 7 January 2026 regarding the commencement of the subscription period in the partially underwritten rights issue (the “Rights Issue”).

Subscription rights were allocated to existing shareholders as of 2 January 2026 (as registered in the VPS as of 6 January 2026). Each subscription right entitles the holder to subscribe for and be allocated one (1) new share at the subscription price in the Rights Issue of NOK 0.50 per share.

Subscribers in the Rights Issue will, without cost, receive warrants in two series: (a) three (3) warrants for every four (4) new shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 2 March 2026 to 13 March 2026 ("Warrants Series 1"); and (b) three (3) warrants for every four (4) new shares allocated to, and paid by them, in the Rights Issue, which will be exercisable in the exercise period from 1 June 2026 to 12 June 2026 ("Warrants Series 2" and together with Warrants Series 1, the "Warrants"). By subscribing for new shares in the Rights Issue, subscribers will at the same time subscribe for the corresponding number of Warrants.

Hannibal Invest AS, a company closely associated with Hans Hekland, board member of the Company, has subscribed for 200,000 new shares in the Rights Issue, of which 187,739 new shares have been subscribed through the exercise of subscription rights, and will as such be allocated to Hannibal Invest AS in accordance with the terms of the Rights Issue. The remaining 12,261 new shares subscribed constitute over-subscription, and there can be no assurance that new shares (or the corresponding number of Warrants as set out below) will be allocated for such over-subscription.

Further, in accordance with the terms of the Rights Issue, Hannibal Invest AS has at the same time subscribed for in total 300,000 Warrants, of which 18,391 Warrants relate to over-subscription.

Please see the attached PDMR form for further details.